Bioxytran (BIXT) investor relations material

Executive summary

• Clinical-stage pharmaceutical company focused on developing therapeutics for stroke and viral diseases, with no revenue generated to date and operations funded primarily through equity and debt offerings.

• Reported a net loss of $2,068,989 for Q1 2026, up from $1,353,635 in Q1 2025, mainly due to a $1,278,600 performance grant to the CEO.

• Cash at quarter-end was $463,047, with negative working capital of $4,547,075 and an accumulated deficit of $23,113,235.

• Ongoing clinical trials for ProLectin-M and BXT-25, with Phase 3 trials contingent on securing additional funding.

Financial highlights

• Operating expenses for Q1 2026 totaled $1,933,053, up from $515,142 in Q1 2025, driven by increased stock-based compensation.

• Research and development expenses were $225,479 in Q1 2026, down from $349,500 in Q1 2025 due to funding constraints.

• General and administrative expenses rose sharply to $1,707,574 in Q1 2026 from $165,642 in Q1 2025, primarily due to the CEO's performance grant.

• Net cash used in operating activities was $238,610, with $200,970 provided by financing activities in Q1 2026.

Outlook and guidance

• Management estimates a need to raise $2-3 million in 2026 to continue operations and fund clinical development.

• Without additional capital, the company may need to extend payables, reduce overhead, or scale back its business plan.

• Phase 3 clinical trials for ProLectin-M and BXT-25 are planned for Q3 2026, pending adequate funding.